Content area
Full Text
Sepracor, Inc., announced publication of its Phase 3B/4 study of Lunesta(TM) (eszopiclone) in patients with insomnia and co-existing major depressive disorder. The article, "Eszopiclone Co-Administered with Fluoxetine in Patients with Insomnia Coexisting with Major Depressive Disorder," is in press and available online in Kological Psychiatry at http://journals.elsevierhealth. com/periodicals/bps/inpress.
This double-blind, placebo-controlled, 10week study evaluated the efficacy and safety of eszopiclone in 545 patients who met criteria for insomnia and major depressive disorder (either newly...